C
Christopher M. Clark
Researcher at Avid Radiopharmaceuticals
Publications - 232
Citations - 28957
Christopher M. Clark is an academic researcher from Avid Radiopharmaceuticals. The author has contributed to research in topics: Dementia & Alzheimer's disease. The author has an hindex of 78, co-authored 191 publications receiving 25984 citations. Previous affiliations of Christopher M. Clark include Graduate Hospital & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis
Manuela Neumann,Deepak M. Sampathu,Linda K. Kwong,Adam C. Truax,Matthew Micsenyi,Thomas T. Chou,Jennifer Bruce,Theresa Schuck,Murray Grossman,Christopher M. Clark,Leo McCluskey,Bruce L. Miller,Eliezer Masliah,Ian R. A. Mackenzie,Howard Feldman,Wolfgang Feiden,Hans A. Kretzschmar,John Q. Trojanowski,Virginia M.-Y. Lee +18 more
TL;DR: It is shown that TDP-43 is the major disease protein in both frontotemporal lobar degeneration with ubiquitin-positive inclusions and amyotrophic lateral sclerosis.
Journal ArticleDOI
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.
Leslie M. Shaw,Hugo Vanderstichele,Malgorzata Knapik-Czajka,Christopher M. Clark,Paul S. Aisen,Ronald C. Petersen,Kaj Blennow,Holly Soares,Adam J. Simon,Piotr Lewczuk,Robert A. Dean,Eric Siemers,William Z. Potter,Virginia M.-Y. Lee,John Q. Trojanowski +14 more
TL;DR: Develop a cerebrospinal fluid biomarker signature for mild Alzheimer's disease (AD) in Alzheimer's Disease Neuroimaging Initiative (ADNI) subjects.
Journal ArticleDOI
Use of Florbetapir-PET for Imaging β-Amyloid Pathology
Christopher M. Clark,Julie A. Schneider,Barry J. Bedell,Thomas G. Beach,Warren B. Bilker,Mark A. Mintun,Michael J. Pontecorvo,Franz Hefti,Alan Carpenter,Matthew Flitter,Michael J. Krautkramer,Hank F. Kung,R. Edward Coleman,P. Murali Doraiswamy,Adam S. Fleisher,Marwan N. Sabbagh,Carl H. Sadowsky,Eric M. Reiman,Simone P. Zehntner,Daniel Skovronsky +19 more
TL;DR: Evidence is provided that a molecular imaging procedure can identify β-amyloid pathology in the brains of individuals during life and for the prediction of progression to dementia.
Journal ArticleDOI
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study
Christopher M. Clark,Michael J. Pontecorvo,Thomas G. Beach,Barry J. Bedell,R. Edward Coleman,P. Murali Doraiswamy,Adam S. Fleisher,Eric M. Reiman,Marwan N. Sabbagh,Carl H. Sadowsky,Julie A. Schneider,Anupa Arora,Alan Carpenter,Matthew Flitter,Abhinay D. Joshi,Michael J. Krautkramer,Ming Lu,Mark A. Mintun,Daniel Skovronsky +18 more
TL;DR: The results of this study validate the binary visual reading method approved in the USA for clinical use with flor betapir and suggest that florbetapir could be used to distinguish individuals with no or sparse amyloid plaques from those with moderate to frequent plaques.
Journal ArticleDOI
Development of cognitive instruments for use in clinical trials of antidementia drugs: Additions to the Alzheimer's Disease Assessment Scale that broaden its scope.
Richard C. Mohs,David S. Knopman,Ronald C. Petersen,Steven H. Ferris,Chris Ernesto,Michael Grundman,Mary Sano,Linas A. Bieliauskas,David S. Geldmacher,Christopher M. Clark,Leon J. Thal +10 more
TL;DR: The cognitive assessment protocol of the Alzheimer's Disease Cooperative Study (ADCS) was designed to evaluate the reliability and validity of cognitive assessment measures that might be valuable additions to the ADAS or other concise batteries used in a concise battery as discussed by the authors.